Last updated: June 12, 2026
Tepmetko suppliers: who manufactures and supplies tepotinib (Tepezza? no) for commercial use
Tepmetko (tepotinib) is supplied in the U.S. market by Merck Sharp & Dohme (MSD) and is manufactured through contract manufacturing and packaging networks typical of branded oncology oral solids, with the active pharmaceutical ingredient (API) and finished dosage form supplied under MSD’s global supply chain. The supplier map, including API source and specific manufacturing site names, is not fully determinable from the information available in this session.
Who supplies Tepmetko (tepotinib) in the U.S. market?
Answer: Merck Sharp & Dohme (MSD) is the labeled U.S. holder and distributor for Tepmetko.
What is the commercial supply chain structure for oral oncology drugs like Tepmetko?
For oral tyrosine kinase inhibitor products, suppliers typically split into:
- API manufacturer (tepotinib synthesis and isolation)
- Finished dose manufacturer (tablet/capsule compression or encapsulation and blend finishing)
- Packager (bottling, labeling, serialization support where applicable)
- Distribution (wholesale channel through branded distribution entities)
What suppliers are listed on the U.S. label or package insert?
The package insert generally names the sponsor and/or U.S. marketing authorization holder rather than listing individual API sites in a supplier-forward way. For supplier identification by site, filings and the FDA drug listing and associated records are typically required.
Which companies manufacture tepotinib (API) for Tepmetko?
Answer: Not determinable from the information available here.
How to interpret “API supplier” vs “finished dose supplier”
- API suppliers are identified via manufacturing records and site-specific inspections tied to drug substance approvals and post-approval changes.
- Finished dose suppliers are identified via drug product manufacturing and packaging records, sometimes visible through site listings in regulatory documentation or inspections.
What are the main finished dosage suppliers for Tepmetko tablets/capsules?
Answer: Not determinable from the information available here.
Which manufacturing steps usually identify different suppliers
- Blending/granulation (if applicable)
- Compression or encapsulation (oral solid dose)
- Coating (if applicable)
- Packaging and labeling (bottle, carton, leaflet assembly)
What does the FDA Orange Book say about Tepmetko manufacturing and supplier partners?
Answer: Not determinable from the information available here.
Why Orange Book is limited for “supplier” attribution
The Orange Book is structured around patent/exclusivity and listing status, not a comprehensive supplier roster. Supplier identity usually requires cross-referencing:
- drug label/labeler (distributor) fields
- FDA listing (labeler/sponsor)
- site-level chemistry, manufacturing, and controls (CMC) references
- inspection databases and post-approval manufacturing change supplements
Are there authorized generic or contract manufacture arrangements for Tepmetko?
Answer: Not determinable from the information available here.
What contract manufacturing signals look like
Commercial tepotinib supply can shift between contract manufacturers after:
- CMC scale changes
- site transfers due to capacity
- change-control supplements
These are only confirmable through specific regulatory and inspection-site records.
Which suppliers support clinical manufacturing of tepotinib for trials?
Answer: Not determinable from the information available here.
Clinical supply often differs from commercial supply
Clinical lots may be manufactured at different sites than commercial batches, even when the same sponsor is responsible.
What supplier changes risk continuity of supply for Tepmetko?
Answer: Not determinable from the information available here.
Risk drivers that typically cause supply disruptions
- Single-site API dependence
- Limited polymer/grade availability for tablet shells (if relevant)
- Serialization or packaging line capacity
- CMC change delays due to comparability data requirements
How does Tepmetko’s supplier network compare with other MET inhibitors?
Answer: Not determinable from the information available here.
Common supplier patterns among oral MET/kinase inhibitors
Oral oncology kinase inhibitors often use:
- one primary API source with secondary qualified sources
- a small set of finished dose CDMOs
- co-packers for packaging/labeling
Comparative mapping requires drug-specific source attribution.
Key Takeaways
- MSD (Merck Sharp & Dohme) is the commercial U.S. supplier/distributor for Tepmetko (tepotinib).
- Specific API and finished-dose manufacturing suppliers cannot be identified from the information available in this session.
- Supplier attribution for tepotinib requires site-level CMC/inspection and FDA listing cross-references, not just Orange Book status or general labeler fields.
FAQs
- Who is the labeler of Tepmetko in the U.S.?
- How can I find Tepmetko API manufacturing sites from regulatory records?
- Do Tepmetko clinical trial supplies come from the same manufacturer as commercial batches?
- What filings indicate manufacturing transfers for Tepmetko?
- What supplier disruptions most often affect oral oncology medicines like Tepmetko?
References
- Merck Sharp & Dohme. Tepmetko (tepotinib) prescribing information. (Source not retrievable in this session.)
- FDA. Orange Book and related drug product records for Tepmetko. (Source not retrievable in this session.)
